| abstract |
The invention relates to a bifunctional fusion protein and its medical use. Specifically, it relates to a bifunctional fusion protein comprising a SIRPĪ³ peptide variant and an anti-human PD-L1 antibody, a SIRPĪ³ peptide variant, and its medical use. According to the bifunctional fusion protein can specifically bind to PD-L1 and CD47, to block the binding of PD-L1 or CD47 to its receptor or ligand. At the same time, the preparation and application of the bifunctional fusion protein and the treatment of cancer and immune-related diseases are also provided. |